Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 4/2012

01.08.2012 | Lung Cancer (T Mekhail, Section Editor)

Current Developments in the Management of Locally Advanced Esophageal Cancer

verfasst von: Michael J. McNamara, David J. Adelstein

Erschienen in: Current Oncology Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Loco-regionally advanced esophageal cancer is a lethal disease with poor outcomes despite aggressive multimodality therapy. The appropriate management of these patients is contentious and no single standard of care has been defined. Literature suggests that preoperative chemoradiotherapy may be superior to preoperative chemotherapy. Recently, several developments have impacted the care of these patients. The 2010 AJCC TNM staging system now recognizes the biologic heterogeneity of the disease and stages adenocarcinoma and squamous cell carcinoma separately. Studies suggest potentially less toxic chemotherapeutic agents including oxaliplatin may be useful in the management of this disease. FDG-PET imaging appears to have prognostic value and may predict for pathologic response. In addition, several trials have explored inhibition of the ErbB1 (EGFR) and ErbB2 (Her2) receptors. The monoclonal antibody trastuzumab appears to extend survival for patients with metastatic gastric and gastroesophageal junction adenocarcinoma and is under investigation for use in patients with loco-regionally advanced disease.
Literatur
1.
Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.PubMedCrossRef
2.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long term follow-up of a prospective randomized trial (RTOG 85–01). JAMA. 1999;281:1623–7.PubMedCrossRef
3.
Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus; FFCD 9102. J Clin Oncol. 2007;25:1160–7.PubMedCrossRef
4.
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Eng J Med. 1996;335:462–7.CrossRef
5.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med. 2001;345:725–30.CrossRef
6.
Allum WH, Stenning SP, Bancewicz J, et al. Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.PubMedCrossRef
7.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med. 2006;335:11–20.CrossRef
8.
• Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92. This is a large meta-analysis which provides strong evidence for a survival benefit from preoperative chemotherapy and chemoradiotherapy as compared to surgery alone in patients with esophageal cancer. The benefits of these treatment modalities are further analyzed by tumor histology.PubMedCrossRef
9.
• Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6. This randomized phase III trial which focused exclusively on patients with adenocarcinoma of the proximal stomach, gastroesophageal junction, and distal esophagus, demonstrated significantly improved pathologic complete response rates with preoperative concurrent chemoradiation compared to preoperative chemotherapy. While there appears to be a trend favoring chemoradiotherapy, the improvements in survival outcomes were not statistically significant.PubMedCrossRef
10.
Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving chemotherapy for adenocarcinoma of the oesophagus? A randomized phase II trial. Eur J Cancer. 2011;47:354–60.PubMedCrossRef
11.
Gaast AV, Van Hagen P, Hulshof D, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. J Clin Oncol. 2010;28:15s (suppl; abstr 4004).
12.
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med. 2008;358:36–46.CrossRef
13.
• Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50–5. This review suggests that oxaliplatin provides greater efficacy with less toxicity than cisplatin in patients with metastatic gastric and gastroesophageal junction adenocarcinoma.PubMedCrossRef
14.
• Conroy T, Yataghene Y, Etienne PL, et al. Phase II randomized trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in esophageal cancer. Br J Cancer. 2010;103:1349–55. This phase II study suggests that concurrent chemoradiotherapy with FOLFOX4 provides a similar degree of benefit as the combination of cisplatin and 5FU.PubMedCrossRef
15.
Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011;29:4555–60.PubMedCrossRef
16.
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721–4.PubMedCrossRef
17.
Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763–73.PubMedCrossRef
18.
Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979–85.PubMedCrossRef
19.
Kelty CJ, Kennedy CW, Falk GL. Ratio of metastatic lymph nodes to total number of nodes resected is prognostic for survival in esophageal carcinoma. J Thorac Oncol. 2010;5:1467–71.PubMedCrossRef
20.
Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovascular Surg. 2007;133:738–45.CrossRef
21.
Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography ([18]F FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472–8.PubMedCrossRef
22.
• Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [18F] Fluorodeoxyglucose positron emission tomography (FDG-PET): can post chemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010;28:4714–21. This retrospective study suggests that patients with a negative FDG-PET after definitive concurrent chemoradiotherapy have improved survival compared with patients who have residual FDG uptake.PubMedCrossRef
23.
Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.PubMedCrossRef
24.
Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesphagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797–805.PubMedCrossRef
25.
• Meyer zum Buschenfelde C, Herrmann K, Schuster T, et al. F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial. J Nucl Med. 2011;52:1189–96. This is a phase II study that employs salvage preoperative chemoradiotherapy in patients who do not demonstrate an early response by FDG-PET to induction chemotherapy.CrossRef
26.
Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004;8:448–53.PubMedCrossRef
27.
Wang KL, Wu T, In SC, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007;109:658–67.PubMedCrossRef
28.
Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with a reduced overall survival in locally advanced oesphageal squamous cell cancer. Br J Cancer. 2005;93:107–15.PubMedCrossRef
29.
Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2005;118:1173–80.CrossRef
30.
Adelstein DJ, Rodriguez CP, Rybicki LA, et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs 2011, [Epub ahead of print].
31.
Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922–6.PubMedCrossRef
32.
Ilson DH, Kelsen D, Shah M, et al. A phase II trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117:1409–14.PubMedCrossRef
33.
Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5:229–35.PubMedCrossRef
34.
Wainberg ZA, Lin L-S, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer. 2011;105:760–5.PubMedCrossRef
35.
Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II southwest oncology group study (S0415). J Thorac Oncol. 2010;5:1472–6.PubMedCrossRef
36.
Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-flourouracil versus cisplatin-5-flourouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667–73.PubMedCrossRef
37.
Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase Ib/II trial (SAKK75/06). J Clin Oncol. 2011;29:626–31.PubMedCrossRef
38.
De Vita F, Orditura M, Martinelli E, et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer. 2011;104:427–32.PubMedCrossRef
39.
Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). J Clin Oncol 2011;29 (suppl; abstr 4046).
40.
Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34:1868–73.PubMedCrossRef
41.
Langer R, Rauser S, Feith M, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridization and fluorescence in situ hybridization. Mod Pathol. 2011;24:908–16.PubMedCrossRef
42.
•• Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–97. This study demonstrates that the addition of trastuzumab to chemotherapy provides a survival advantage for patients with metastatic gastric and gastroesophageal adenocarcinoma who express HER2.PubMedCrossRef
43.
Safran H, DiPetrillo T, Akerman P, et al. PhaseI/II study of trastuzumab, paclitaxel, cisplatin, and radiation for locally advanced, Her2 overexpressing, esophageal adenocarcinoma. Int J Radiation Oncology Biol Phys. 2007;67:405–9.CrossRef
44.
Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261–8.PubMedCrossRef
45.
Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22:1367–73.PubMedCrossRef
Metadaten
Titel
Current Developments in the Management of Locally Advanced Esophageal Cancer
verfasst von
Michael J. McNamara
David J. Adelstein
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 4/2012
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0239-7

Weitere Artikel der Ausgabe 4/2012

Current Oncology Reports 4/2012 Zur Ausgabe

Sarcomas (SR Patel, Section Editor)

Current State-of-the-Art Systemic Therapy for Pediatric Soft Tissue Sarcomas

Palliative Medicine (A Jatoi, Section Editor)

The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients

Lung Cancer (T Mekhail, Section Editor)

Thymic Neoplasms: a Clinical Update

Sarcomas (SR Patel, Section Editor)

Progress in Radiotherapy for Pediatric Sarcomas

Palliative Medicine (A Jatoi, Section Editor)

Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers

Palliative Medicine (A Jatoi, Section Editor)

VEGF Inhibition, Hypertension, and Renal Toxicity

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise